Northwest Biotherapeutics has appointed Dr. Annalisa Jenkins as a Strategic Adviser to support the development of its DCVax® dendritic cell-based cancer vaccine platform, focusing on glioblastoma and other solid tumors. Dr. Jenkins brings over 25 years of biopharma leadership and expertise in drug development, regulatory strategy, and commercialization. The company is currently reviewing its Marketing Authorization Application for DCVax-L in the UK and plans to expand its vaccine technology to treat a broad range of solid tumors. This appointment aims to accelerate the development and patient access to innovative immunotherapies for difficult cancers.
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
